No Data
Sinolink Securities: Pharmaceutical prosperity in the third quarter hovers at the bottom, focusing on the improvement prospects for the next 25 years.
In the third quarter, due to internal adjustments in the healthcare sector, changes in the consumer environment, and some medical insurance cost control policies still being implemented, the business climate continued to bottom out in the Q3 report, with a slower rebound than expected.
Additional Considerations Required While Assessing Xiamen Amoytop Biotech's (SHSE:688278) Strong Earnings
Xiamen Amoytop Biotech Q3 Profit Up 50%, Revenue Rises 38%
Tebao Biotech: Third quarter report 2024
Xiamen Amoytop Biotech (688278.SH) released its performance for the first three quarters, with a net income of 0.554 billion yuan, a year-on-year increase of 50.21%.
Xiamen Amoytop Biotech (688278.SH) disclosed the third quarter report for 2024, with the company achieving revenue of 19...
Xiamen Amoytop Biotech (688278.SH): The net income for the first three quarters was 0.554 billion yuan, a year-on-year increase of 50.21%.
On October 24th, Gelonghui reported that Xiamen Amoytop Biotech (688278.SH) released its third quarter report for 2024, with the company's revenue in the first three quarters reaching 1.955 billion yuan, a year-on-year increase of 33.90%; the net income attributable to shareholders of the listed company was 0.554 billion yuan, a year-on-year increase of 50.21%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.581 billion yuan, a year-on-year increase of 41.34%; with an EPS of 1.36 yuan.
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention TodayNo Data
No Data
